A study of over 1 million people has found impressive dementia risk reductions linked to cholesterol management — offering some of the strongest evidence yet on how long-term LDL lowering affects brain health.
There has been considerable controversy surrounding how cholesterol relates to brain health. Could lowering blood cholesterol levels be helpful? Or could it be harmful? This new research provides fresh data that helps clarify what's going on. This article also covers the key risk factors for dementia that are within our control — backed by the latest evidence.
Table of Contents
- The Worry
- Does Lowering LDL Cholesterol Help?
- The New Study
- Practical Guidelines
- A Cluster of Related Risk Factors
- Four Surprising Risk Factors
- Supplements That May Help
- Conclusion
- References
The Worry
A long-standing concern in medicine: could lowering blood cholesterol levels actually harm brain health?
The brain is packed with cholesterol and holds about 20% of the body's total supply [1].
Cholesterol in the brain is crucial for building the structures that enable neurons to communicate. It also plays a role in controlling the flow of that communication. The question then becomes: if blood cholesterol levels are lowered too much, could this starve the brain of a crucial resource? [2]
Interestingly, cholesterol does not cross the blood-brain barrier. The cholesterol in the brain does not arrive from the bloodstream — it is synthesized within the brain itself [1].
This means that lowering blood cholesterol by modifying diet should not be an issue. But the story is different with cholesterol-lowering medications like statins. Some evidence suggests they can cross the blood-brain barrier and lower cholesterol levels within brain tissue [3].
That is the theory. But the evidence at present comes mostly from lab or animal studies. Is there any evidence that statins negatively affect the brain in the real world?
Early on, doctors began to notice cases where statin use was suspected of being linked to memory loss. A study published in 2003 catalogued and analyzed 60 such cases. In many of them, stopping statins led to an improvement in symptoms. In fact, 56% of patients who stopped taking statins noticed improved memory [4].
But this kind of evidence is only suggestive. Randomized, controlled trials are needed to really understand the effects of statins on cognitive health.
Results from the PROSPER study were published in 2010. Researchers looked at the effects of pravastatin compared to placebo in a group of elderly patients. After an average follow-up of 42 months, they found no difference in measures of cognitive decline between the two groups [5].
A more recent study analyzed the impact of achieving very low LDL cholesterol levels through a combination of statins and a different type of cholesterol-lowering medication called a PCSK9 inhibitor. The median follow-up was around 5 years. Again, no negative cognitive effects were associated with treatment [6].
Does Lowering LDL Cholesterol Help?
So from the evidence available, statins and PCSK9 inhibitors do not appear to harm cognitive health. But could they help?
Here the research enters an ongoing controversy.
Observational studies seem to suggest one answer. A meta-analysis published in 2024 combined 55 observational studies including over 7 million patients. The researchers found that statin use cut the risk of dementia by 14%. For those who used statins for more than 3 years, however, the risk reduction was a massive 63% [7].
What might explain this link?
There are two main types of dementia.
Vascular dementia results from plaque building up in the arteries that supply the brain, leading to reduced oxygen flow and brain cell damage [8].
Alzheimer's disease, on the other hand, is caused by the accumulation of amyloid-beta plaques and neurofibrillary tangles in the brain, leading to inflammation, synaptic dysfunction, and memory loss [9].
A key way statins help is by lowering LDL cholesterol. High LDL is a central causal factor in plaque accumulation, and this accumulation plays a role in both types of dementia [10].
Further, statins have anti-inflammatory and antioxidant effects. These have also been proposed as mechanisms to counter dementia [11].
There is a plausible biological basis for the link seen in observational studies. However, these studies only show association — not causation.
Some researchers suggest that the benefits seen in observational studies may be due in part to a "healthy user bias." This is when individuals receiving preventative treatments like statins are also more likely to engage in other health-protective activities, such as exercising or eating well [11].
That is why randomized controlled trials are crucial. But here is where things get puzzling.
A new meta-analysis of 20 randomized controlled trials with over 100,000 participants, published in August 2024, found that lowering LDL cholesterol through medication did not significantly reduce the risk of dementia [12].
On the bright side, it also found no harm to cognitive health — providing more reassurance against earlier worries.
So why the disconnect between observational studies and clinical trials?
One explanation is time. Observational studies often cover longer periods, while trials usually last only a few years. The protective effects of statins may take decades to appear — especially if started earlier in life [12].
Supporting this, studies show that younger patients (mean age ≤70 years) benefit more from statins for dementia prevention than older ones [11]. Additionally, LDL cholesterol levels in mid-life are linked to higher Alzheimer's risk later in life [13].
Taken together, this suggests that statins might need to be used long-term, starting in mid-life, to protect brain health — a pattern that short-term trials might miss.
The New Study
This brings us to a new study of over 1 million people — one of the most compelling yet.
Instead of using a traditional randomized controlled trial, the researchers used a Mendelian randomization approach. This method examines people who are born with specific genetic variants that mimic the effects of cholesterol-lowering drugs. These individuals essentially experience a lifelong "simulation" of being on a statin or similar medication — without actually taking one.
This provides something that mimics a randomized trial — but over an entire lifetime, rather than just a few years.
In this study, researchers looked at genetic variants that affect three types of cholesterol-lowering medications:
- Statins (targeting HMG-CoA reductase / HMGCR)
- Ezetimibe (blocking NPC1L1, a cholesterol absorption protein)
- PCSK9 inhibitors (which affect LDL receptor recycling) [14]
They calculated dementia risk reduction per 39 mg/dL (1 mmol/L) lower non-HDL cholesterol — a metric that includes LDL and other harmful particles [14].
The results were truly impressive:
- Statin-mimicking genes: 76% risk reduction
- Ezetimibe-mimicking genes: 82% risk reduction [14]
This strongly supports the idea that long-term cholesterol lowering — via any of these pathways — is highly protective against dementia.
But there was one surprising finding.
Genetic variants that mimic PCSK9 inhibitors did not show consistent benefits. One analysis showed a protective effect, but two others showed none [14].
That is surprising, because PCSK9 inhibitors are the most powerful LDL-lowering drugs available [15].
This raises a fascinating possibility: it's not just how much LDL cholesterol is lowered that matters — but how it is lowered.
Practical Guidelines
What can be taken from all this?
The evidence linking high LDL cholesterol to dementia is now strong enough that the Lancet Commission listed it as a key modifiable risk factor in its 2024 dementia report [16].
Lowering LDL cholesterol — already essential for heart health — may also help protect the brain.
The Lancet lists 14 modifiable risk factors in total. Addressing these could potentially prevent up to 45% of dementia cases [16].
Below are some of the most important — and surprising — ones.
A Cluster of Related Risk Factors
These four are tightly interlinked and associated with cholesterol levels:
- Inactivity
- Type 2 diabetes
- High blood pressure
- Obesity [16]
Managing these through proper diet and exercise is essential.
Four Surprising Risk Factors
1. Mental Stimulation
Just as muscles need to be used, so do brains. Research involving over 107,000 people found that those with high cognitive stimulation at work had a lower risk of dementia.
- Low education + high cognitive stimulation: 20% lower risk
- High education + high cognitive stimulation: 37% lower risk [16]
Continuing to learn and challenge the mind is a proven way to help protect brain health.
2. Hearing Loss
Around 20% of people globally experience hearing loss. Untreated hearing loss is strongly linked to dementia.
In a series of studies, those with hearing loss had up to 2.4x the risk of developing dementia. For every 10-decibel worsening of hearing, the risk increased by 16% [16].
The good news: hearing aids help. A meta-analysis showed people who used them had significantly lower risk of both cognitive decline (19% lower) and dementia (17% lower) [16].
3. Vision Loss
A major meta-analysis of 14 studies, following over 6 million older adults, found that vision loss was associated with a 47% increased risk of developing dementia [16].
For those with visual impairment, regular eye exams and timely treatment are important for protecting cognitive health.
4. Depression
Depression more than doubles the risk of dementia. A pooled analysis showed a relative risk (RR) of 2.25 [16].
Treating depression is associated with meaningful reductions in dementia risk. Those treated with:
- Pharmacotherapy: 23% lower dementia risk
- Psychotherapy: 26% lower
- Combined therapy: 38% lower
Overall, treatment reduced dementia risk by 31% compared to untreated individuals [16].
Other Notable Factor: Social Isolation
Loneliness and infrequent social contact are also strongly linked to cognitive decline.
Systematic reviews found that social isolation increased dementia risk by between 18% and 57%, depending on the study [16].
Supplements That May Help
Three supplements have meaningful scientific backing for cognitive benefits.
1. Multivitamin & Mineral
A large clinical trial over 2 years showed that daily multivitamin and mineral supplementation improved global cognition and episodic memory.
The effect was equivalent to reversing 2 years of brain aging [17].
2. Creatine
Best known for supporting exercise performance, creatine also benefits brain health.
It helps fuel brain cells by supporting rapid energy production. Supplementation has been shown to increase brain creatine content [18].
A 2022 meta-analysis found that creatine improved memory performance, especially in older adults aged 66–76 [19].
3. TMG (Trimethylglycine)
In 2020, a large-scale review of Alzheimer's risk factors found that high homocysteine levels were strongly associated with the disease [20].
Homocysteine-lowering treatments were identified among the most promising interventions for Alzheimer's prevention [21].
TMG has been shown in multiple studies to lower homocysteine significantly [22], making it a candidate worth considering for those interested in this area of research.
From the MicroVitamin range
MicroVitamin+ Powder contains creatine and TMG alongside a full multivitamin and mineral blend — the three supplements discussed in this section. MicroVitamin+ Powder.
Conclusion
The data is clear: dementia risk can be significantly reduced, and long-term management of LDL cholesterol plays a key role — not just for heart health, but for the brain as well.
Research in this area continues to advance rapidly. This massive new study, drawing on over one million participants, provides some of the strongest evidence yet that cholesterol management — and the specific method used — matters deeply for long-term brain health. Understanding these mechanisms may open new avenues for prevention in the years ahead.
References
1. https://pmc.ncbi.nlm.nih.gov/articles/PMC6844833/
2. https://pubmed.ncbi.nlm.nih.gov/22269162/
3. https://translationalneurodegeneration.biomedcentral.com/articles/10.1186/s40035-018-0110-3
4. https://pubmed.ncbi.nlm.nih.gov/12885101/
5. https://pubmed.ncbi.nlm.nih.gov/19653027/
6. https://evidence.nejm.org/doi/full/10.1056/EVIDoa2400112
7. https://pmc.ncbi.nlm.nih.gov/articles/PMC11736423/
8. https://www.ncbi.nlm.nih.gov/books/NBK430817/
9. https://www.mdpi.com/2813-2564/4/1/2
10. https://www.nature.com/articles/s41598-022-24153-1
11. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830700/
12. https://pmc.ncbi.nlm.nih.gov/articles/PMC12341882/
13. https://www.sciencedirect.com/science/article/pii/S2405650225000449
14. https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70638
15. https://pmc.ncbi.nlm.nih.gov/articles/PMC6380691
16. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2824%2901296-0/abstract
17. https://pmc.ncbi.nlm.nih.gov/articles/PMC11103094/
18. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8912287/
19. https://academic.oup.com/nutritionreviews/advance-article/doi/10.1093/nutrit/nuac064/6671817
20. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7569385/
